REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
Rhea-AI Summary
REGENXBIO (RGNX) has scheduled a conference call for Thursday, March 13, at 4:30 p.m. ET to present its fourth quarter and full-year 2024 financial results along with recent operational updates. The presentation will be accessible through a webcast, with a dedicated link for analysts who wish to participate in the Q&A session. Participants are advised to join 15 minutes before the start time, and a replay will be made available on the company's investor website approximately two hours after the call concludes.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RGNX declined 1.05%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-march-13-to-discuss-fourth-quarter-and-full-year-2024-financial-results-and-recent-operational-highlights-302385846.html
SOURCE REGENXBIO Inc.
FAQ
When is REGENXBIO (RGNX) reporting Q4 and full-year 2024 earnings?
How can investors access RGNX's Q4 2024 earnings call?
Will there be a replay available for RGNX's Q4 2024 earnings call?
What time should participants join RGNX's Q4 2024 earnings call?
